Krystal Biotech (KRYS) to Offer $100M in Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- Wall St muted after Fed Chair Warsh's speech; AI rally cools
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil drifts lower as Hormuz flows balance slow progress in Iran diplomacy
- Dollar climbs after Warsh comments, poised for weekly gain
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Ovintiv adds 41,000 acres in Permian and Montney deals
- BioNTech ends colorectal cancer mRNA therapy trial early
Krystal Biotech Announces Proposed $100 Million Public Offering of Common Stock
February 2, 2021 4:10 PM ESTPITTSBURGH--(BUSINESS WIRE)-- Krystal Biotech Inc. (NASDAQ: KRYS) (the Company), the leader in redosable gene therapies for rare diseases, today announced that it has commenced a $100 million underwritten public offering of its common stock. The Company intends to grant the underwriters a 30-day option to purchase an additional 15% of the shares of its common stock offered in the public offering. The offering is subject to market and other conditions, and there can be no assurances as to whether or when the offering may be completed, or as to the actual size... More
